Breaking News Instant updates and real-time market news.

AMC

AMC Entertainment

$13.04

-0.16 (-1.21%)

, CUBI

Customers Bancorp

$20.81

-0.23 (-1.09%)

04:55
05/23/19
05/23
04:55
05/23/19
04:55

B. Riley FBR to hold a conference

20th Annual Institutional Investor Conference will be held in Beverly Hills, CA on May 22-23.

AMC

AMC Entertainment

$13.04

-0.16 (-1.21%)

CUBI

Customers Bancorp

$20.81

-0.23 (-1.09%)

ACST

Acasti Pharma

$0.91

0.01 (1.11%)

MAMS

MAM Software

$8.95

0.045 (0.51%)

BW

Babcock & Wilcox

$0.48

0.0543 (12.62%)

HL

Hecla Mining

$1.39

-0.065 (-4.47%)

FBIO

Fortress Biotech

$1.93

(0.00%)

HIIQ

Health Insurance Innovations

$25.49

-0.82 (-3.12%)

NG

NovaGold

$3.80

-0.035 (-0.91%)

MNOV

MediciNova

$11.50

0.52 (4.74%)

IMI

Intermolecular

$1.18

(0.00%)

CHMI

Cherry Hill Mortgage

$17.12

-0.18 (-1.04%)

ARC

ARC Document

$2.11

-0.03 (-1.40%)

CARB

Carbonite

$25.19

-0.56 (-2.17%)

BHR

Braemar Hotels & Resorts

$12.20

-0.115 (-0.93%)

CTG

Computer Task Group

$4.47

0.025 (0.56%)

CSWC

Capital Southwest

$22.27

-0.04 (-0.18%)

NLS

Nautilus

$3.11

-0.07 (-2.20%)

INSW

International Seaways

$19.61

-0.08 (-0.41%)

FNV

Franco-Nevada

$74.16

-1.78 (-2.34%)

DLA

Delta Apparel

$22.13

0.6 (2.79%)

LOV

Spark Networks

$13.34

0.14 (1.06%)

MOTS

Motus GI Holdings

$3.34

-0.39 (-10.46%)

PDFS

PDF Solutions

$12.26

-0.14 (-1.13%)

ELY

Callaway Golf

$15.33

0.48 (3.23%)

  • 28

    May

  • 28

    May

  • 30

    May

  • 30

    May

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 10

    Jun

  • 12

    Jun

  • 12

    Jun

  • 13

    Jun

  • 14

    Jun

  • 18

    Jun

  • 25

    Jun

  • 07

    Aug

  • 08

    Aug

  • 24

    Oct

AMC AMC Entertainment
$13.04

-0.16 (-1.21%)

04/08/19
04/08/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wynn Resorts (WYNN) upgraded to Buy from Hold at Jefferies with analyst David Katz citing better than expected gross gaming revenue results from Macau for March and signs that suggest to him that it is reasonable to expect economic improvement throughout 2019 in China. 2. e.l.f. Beauty (ELF) upgraded to Neutral from Underweight at JPMorgan. 3. Procter & Gamble (PG) upgraded to Outperform from Market Perform at Wells Fargo with analyst Bonnie Herzog telling investors that while she is "late to the game," she still sees upside and believes P&G has changed and management, led by CEO David Taylor, has infused a sense of urgency and accountability into the organization. 4. AMC Entertainment (AMC) upgraded to Buy from Neutral at B. Riley FBR with analyst Eric Wold saying he has an "increasingly optimistic" view of the EBITDA contribution from Stubs A-List. 5. Zillow (Z, ZG) upgraded to Outperform from Market Perform at Cowen with analyst Thomas Champion saying he believes the new duo of CEO Rich Barton and CFO Allen Parker look well suited for the "massive challenge" of leading the company through a change in business model. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/08/19
RILY
04/08/19
UPGRADE
Target $20
RILY
Buy
AMC Entertainment upgraded to Buy from Neutral at B. Riley FBR
B. Riley FBR analyst Eric Wold upgraded AMC Entertainment to Buy from Neutral and raised his price target for the shares to $20 from $18. The analyst has an "increasingly optimistic" view of the EBITDA contribution from Stubs A-List. Further, he views the spring/summer film slates and AMC's upcoming analyst day as positive catalysts.
05/13/19
BNCH
05/13/19
NO CHANGE
Target $17
BNCH
Buy
AMC Entertainment price target lowered to $17 from $20 at Benchmark
Benchmark analyst Mike Hickey lowered his price target on AMC Entertainment to $17 from $20 after the company's mixed Q1 results, noting that management said they remain confident they can achieve records in both sales and adjusted EBITDA this year. The analyst, who keeps a Buy rating on AMC shares, sees the domestic box office growing 10% in Q2.
04/12/19
MKMP
04/12/19
NO CHANGE
Target $16
MKMP
Neutral
AMC Entertainment price target lowered to $16 at MKM Partners on weak box office
MKM Partners analyst Eric Handler nudged his price target on AMC Entertainment lower to $16 from $17 and kept his Neutral rating, saying the soft 2019 start from weaker than anticipated box office has added pressure on the summer to show improvement. The analyst is also lowering his Q1 and FY19 EPS outlook to (76c) from (44c) and to (66c) from (34c) respectively - levels that are at or near the lows for the Street and well below consensus. Handler expects the management of AMC Entertainment to provide more clarity about the incremental profit potential of its A-List subscription service at the investor event next week.
CUBI Customers Bancorp
$20.81

-0.23 (-1.09%)

04/11/19
04/11/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Five Below (FIVE) upgraded to Overweight from Neutral at JPMorgan with analyst Matthew Boss saying management expressed "strong confidence" in both the near-term and multi-year 20%-plus sales growth driving 20%-plus annual earnings growth. 2. CMS Energy (CMS) upgraded to Buy from Neutral at BofA/Merrill with analyst Julien Dumoulin-Smith saying shares are more attractive following recent underperformance and have been de-risked by the resolution of PURPA issues through the IRP settlement, removing the biggest overhang. 3. Cracker Barrel (CBRL) upgraded to Buy from Hold at Maxim. 4. Customers Bancorp (CUBI) upgraded to Buy from Neutral at B. Riley FBR with analyst Steve Moss saying with the T-Mobile launch imminent, the he finds the risk/reward attractive with the stock trading at 84% of tangible book value. 5. Hawaiian Holdings (HA) upgraded to Outperform from Neutral at Macquarie with analyst Susan Donofrio saying she believes investor sentiment is beginning to shift as concerns over Southwest (LUV) dramatically changing the pricing structure abate and raised estimates to reflect stronger expected earnings. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/30/18
MAXM
10/30/18
NO CHANGE
Target $38
MAXM
Buy
Customers Bancorp price target lowered to $38 from $46 at Maxim
Maxim analyst Steven Chercover lowered his price target on Customers Bancorp to $38. The analyst cites the company's Analyst Day announcement that the BankMobile spin/merge with Flagship Community Bank will not take place at this time due to Federal Reserve Board non-approval as well as the net interest margin contraction of 15bps reported in its Q3 earnings last week. Chercover also kept his Buy rating on Customers Bancorp, adding that the bank's valuation is in line with the "multiples of the high-quality small-cap banks" that he follows.
04/11/19
RILY
04/11/19
UPGRADE
Target $30
RILY
Buy
Customers Bancorp upgraded to Buy from Neutral at B. Riley FBR
B. Riley FBR analyst Steve Moss upgraded Customers Bancorp to Buy from Neutral and raised his price target for the shares to $30 from $23. With the T-Mobile launch imminent, the analyst finds the risk/reward attractive with the stock trading at 84% of tangible book value.
11/08/18
RILY
11/08/18
DOWNGRADE
Target $23
RILY
Neutral
Customers Bancorp downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Steve Moss downgraded Customers Bancorp to Neutral and lowered his price target for the shares to $23 from $29. The analyst sees "too many moving pieces" and limited earnings visibility.
ACST Acasti Pharma
$0.91

0.01 (1.11%)

MAMS MAM Software
$8.95

0.045 (0.51%)

BW Babcock & Wilcox
$0.48

0.0543 (12.62%)

HL Hecla Mining
$1.39

-0.065 (-4.47%)

05/10/19
JPMS
05/10/19
DOWNGRADE
JPMS
Neutral
Hecla Mining downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst John Bridges downgraded Hecla Mining to Neutral from Overweight.
05/13/19
BMOC
05/13/19
DOWNGRADE
BMOC
Underperform
Hecla Mining downgraded to Underperform from Market Perform at BMO Capital
05/13/19
BMOC
05/13/19
DOWNGRADE
Target $1.1
BMOC
Underperform
Hecla Mining downgraded to Underperform from Market Perform at BMO Capital
BMO Capital analyst Ryan Thompson downgraded Hecla Mining to Underperform and lowered his price target to $1.10 from $1.80 after its Q1 earnings miss, saying the results also revealed an additional $85M drawn on its revolver. The analyst calls the company's balance sheet as "too stretched for comfort" and believes that the possibility of a covenant breach on its bank debt is high. Thompson further believes that an attempt by Hecla Mining to raise equity would meet a "challenging market" while an asset sale is unlikely to generate the assumed cash values.
05/14/19
CIBC
05/14/19
DOWNGRADE
CIBC
Underperformer
Hecla Mining downgraded to Underperformer from Neutral at CIBC
FBIO Fortress Biotech
$1.93

(0.00%)

02/20/19
HCWC
02/20/19
NO CHANGE
HCWC
Mustang Bio partnership adds 'shots on goal' to portfolio, says H.C. Wainwright
After Mustang Bio (MBIO), one of Fortress Biotech's (FBIO) subsidiaries, announced a partnership and exclusive worldwide license agreement with Nationwide Children's Hospital, H.C. Wainwright analyst Joseph Pantginis said he believes the pact adds "shots on goal" to Mustang's portfolio and could reinforce confidence in the company's CAR-T programs. After having recently sat down with Fortress' management, Pantginis said the "major announcements as of late" from its subsidiaries show to him that the Fortress portfolio model is working. The analyst, who does not have a rating on Mustang Bio, keeps a Buy rating and $11 price target on Fortress Biotech shares.
04/18/19
HCWC
04/18/19
NO CHANGE
HCWC
H.C. Wainwright says Fortress business model validated by Mustang data
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $11 price target on Fortress Biotech (FBIO), noting that Mustang Bio (MBIO), a Fortress Biotech Company, published positive data related to its Phase 1/2 trial in children with XSCID, also known as bubble boy disease, delivering "compelling safety and efficacy." Pantginis sees Fortress continuing "to participate in the shares' appreciation showing continued validation of its business model."
02/13/19
HCWC
02/13/19
NO CHANGE
Target $11
HCWC
Buy
Fortress Biotech share 'disconnect' presents opportunity, says H.C. Wainwright
After meeting with management, H.C. Wainwright analyst Joseph Pantginis reiterates a Buy rating on Fortress Biotech with an $11 price target. The company's announcements of late show its portfolio model is working, Pantginis tells investors in a research partially titled, "Portfolio Model Working, So Should Stock." However, the analyst believes a "disconnect still exists in the shares presenting an opportunity for investors to take part in further portfolio newsflow." There can be eight programs filing for approval in the next 12-36 months, of which Fortress would be entitled to "meaningful economics" as well as its ownership positions, says Pantginis.
HIIQ Health Insurance Innovations
$25.49

-0.82 (-3.12%)

05/07/19
LSCM
05/07/19
NO CHANGE
Target $50
LSCM
Buy
Health Insurance Innovations price target lowered to $50 from $80 at Lake Street
Lake Street analyst Mark Argento lowered his price target for Health Insurance Innovations to $50 from $80 following the company's Q1 results while keeping a Buy rating on the shares. Strong policy duration growth has been offset by lower new policy adds and higher duration and expenses in the last two quarters, which is likely to persist in Q2 given management's updated quarterly guidance, Argento tells investors in a research note. The analyst points out that Health Insurance's fiscal 2019 guidance is now increasingly back-end loaded.
03/29/19
ADAM
03/29/19
NO CHANGE
Target $62
ADAM
Buy
New court filings read positive for Health Insurance Innovations, says Canaccord
Canaccord analyst Richard Close said a court filing in the case of the FTC versus Steven Dorfman gives him increased confidence that Health Insurance Innovations is not a target of the FTC and has "minimal, if any," legal concerns over this matter. His read of the documents leads Close to believe the FTC's position is that Health Insurance Innovations is not responsible for demonstrating that products sold by Simple Health provide benefits and value and the FTC "appears not to be shifting any blame" to the company, the analyst tells investors. He keeps a Buy rating and $62 price target on Health Insurance Innovations shares.
05/02/19
RAJA
05/02/19
NO CHANGE
Target $50
RAJA
Outperform
Health Insurance Innovations stock looks 'broken,' says Raymond James
Raymond James analyst C. Gregory Peters keeps an Outperform rating on Health Insurance Innovations shares, but said he fears the stock "appears to be broken" and could see additional weakness as broker-dealers have to short more shares to keep their books neutral if the stock continues to slide. While he does not believe that legislation introduced in the House of Representatives to prevent the enforcement of a recent regulation aimed at increasing the number of people with short-term limited duration insurance will see action in the Senate, Peters acknowledges the overhang that the bill has been on Health Insurance Innovations shares.
05/08/19
CANT
05/08/19
NO CHANGE
Target $75
CANT
Overweight
Cantor views new Health Insurance disclosure on Simple Health positively
Health Insurance Innovations last night in its quarterly filing updated its disclosure regarding the ongoing dispute between the FTC and one of its former distributors, Simple Health, Cantor Fitzgerald analyst Steven Halper told investors earlier in a research note. The disclosure indicates that Health Insurance is not a defendant or party in the case and has been in regular dialogue with the FTC, says the analyst. He views the disclosure positively and reiterates his view that concerns regarding the company's exposure to FTC lawsuit against Simple Health are "entirely overblown." Shares of Health Insurance Innovations are up 8c to $22.02 in morning trading.
NG NovaGold
$3.80

-0.035 (-0.91%)

MNOV MediciNova
$11.50

0.52 (4.74%)

03/25/19
RILY
03/25/19
INITIATION
Target $22
RILY
Buy
MediciNova asumed with a Buy at B. Riley FBR
B. Riley FBR analyst Chad Mabry assumed coverage of MediciNova with a Buy rating and $22 price target.
IMI Intermolecular
$1.18

(0.00%)

01/04/19
LSCM
01/04/19
NO CHANGE
Target $3
LSCM
Buy
Lake Street more confident on Intermolecular after management call
After hosting a call with CEO Chris Kramer and CFO Bill Roeschlein, Lake Street analyst Jaeson Schmidt has increased confidence that Intermolecular is positioned to see sustained top line growth and improving profitability this year and next. The analyst continues to like how shares are set up for this year saying growth should no longer be "masked" and year-over-year comps get easier in the second half of 2019. Further, with 58% of the market cap in cash and the recently announced $10M buyback program, there should be a "relatively high floor" on Intermolecular shares in the near-term, contends Schmidt. He reiterates a Buy rating on the stock with a $3 price target.
02/13/19
LSCM
02/13/19
NO CHANGE
Target $3
LSCM
Buy
Intermolecular guidance does not overshadow contract momentum, say Lake Street
Lake Street analyst Jaeson Schmidt says that while he was expecting a stronger Q1 outlook from Intermolecular, he does not believe the story has significantly changed. The company remains on track to see growth resume this year, Schmidt tells investors in a post-earnings research note titled "Softer Guidance Should Not Overshadow Continued Contract Momentum And Attractive Valuation; Reiterating BUY Rating And $3 PT." Further, he's encouraged by the new customer contract and the "strong" gross margin expected in Q1 and throughout this year. Schmidt continues to like the risk/reward opportunity for Intermolecular shares and keeps a Buy rating on the name with a $3 price target.
06/28/18
LSCM
06/28/18
INITIATION
Target $3
LSCM
Buy
Intermolecular initiated with a Buy at Lake Street
Lake Street analyst Jaeson Schmidt started Intermolecular with a Buy rating and $3 price target. The analyst thinks the company is approaching an inflection point where revenue growth will accelerate and earnings will expand as it emerges from its turnaround and benefits from increasing complexity in the semiconductor manufacturing process. With 34% of the market capitalization in cash, and the stock trading at only 2.5 times tangible book, the shares have a "relatively solid backstop," Schmidt tells investors in a research note.
05/06/19
LSCM
05/06/19
DOWNGRADE
LSCM
Hold
Intermolecular downgraded to Hold from Buy at Lake Street
Lake Street analyst Jaeson Schmidt downgraded Intermolecular (IMI) to Hold from Buy after the company announced an agreement to be acquired by a subsidiary of Merck KGaA (MKGAY) for $1.20 per share in cash.
CHMI Cherry Hill Mortgage
$17.12

-0.18 (-1.04%)

06/18/18
WEDB
06/18/18
UPGRADE
Target $19.5
WEDB
Outperform
Cherry Hill Mortgage upgraded to Outperform from Neutral at Wedbush
Wedbush analyst Henry Coffey upgraded Cherry Hill Mortgage to Outperform from Neutral, with a $19.50 price target. Following its recent stock offering, the company's pro-forma post offering book value per share is estimated to be $19.65, he contends. The analyst notes that the total return for Cherry Hill Mortgage adds to 17%. In Coffey's view, this is high enough to warrant purchase at current levels.
ARC ARC Document
$2.11

-0.03 (-1.40%)

08/03/18
RILY
08/03/18
UPGRADE
Target $3.25
RILY
Buy
ARC Document upgraded to Buy from Neutral at B. Riley FBR
B. Riley FBR analyst Josh Nichols upgraded ARC Document Solutions to Buy and raised his price target for the shares to $3.25 from $2.75. The analyst views the company's Q2 results as "strong" and is positive on its growth trajectory.
CARB Carbonite
$25.19

-0.56 (-2.17%)

02/08/19
RSBL
02/08/19
DOWNGRADE
Target $33
RSBL
Neutral
Carbonite downgraded to Neutral from Buy at Rosenblatt
As previously reported, Rosenblatt analyst Marshall Senk downgraded Carbonite to Neutral from Buy and lowered his price target to $33 from $45 following the company's Q4 results and announcement that it will buy Webroot for roughly $618.5M in cash. In a research note to investors, Senk says he is "concerned" about the slowing in Carbonite's core business and the crowded nature of the endpoint space, and says it could take until mid-year or longer to get a perspective on where real, organic growth resides for the cor business and to begin to get a sense of the timing of revenue synergies with Webroot.
03/28/19
LEHM
03/28/19
INITIATION
Target $30
LEHM
Overweight
Carbonite reinstated with an Overweight at Barclays
Barclays analyst Saket Kalia reinstated coverage of Carbonite with an Overweight rating and $30 price target. The analyst sees strategic rationale of the company's Webroot acquisition.
02/08/19
RSBL
02/08/19
DOWNGRADE
RSBL
Neutral
Carbonite downgraded to Neutral from Buy at Rosenblatt
02/08/19
LSCM
02/08/19
NO CHANGE
Target $39
LSCM
Buy
Carbonite price target raised to $39 from $36 at Lake Street
Lake Street analyst Eric Martinuzzi raised his price target for Carbonite to $39 saying the Webroot acquisition "checks all the boxes." Carbonite is not only expanding into the attractive cybersecurity market with an offering that should be an easy cross-sell, it is only paying 2.6 times enterprise value to 2019 revenue for an accretive endpoint security software business, Martinuzzi tells investors in a research note. He keeps a Buy rating on Carbonite shares while admitting that the company's legacy business "did not impress" in Q4.
BHR Braemar Hotels & Resorts
$12.20

-0.115 (-0.93%)

08/06/18
DBAB
08/06/18
NO CHANGE
Target $15
DBAB
Buy
Braemar valuation 'too compelling to ignore,' says Deutsche Bank
Deutsche Bank analyst Chris Woronka believes the valuation of Braemar Hotels & Resorts is "too compelling to ignore." Even based on 2019 estimated enterprise value to EBITDA and taking into account the termination fee payable to its advisor, Braemar is trading at a material discount to its most comparable hotel REIT peers, Woronka tells investors in a research note. And that's not giving any credit for the embedded growth the portfolio should have once three major capital projects are fully ramped in 2020-2021, the analyst adds. He raised his price target for Braemar Hotels & Resorts to $15 from $14 and keeps a Buy rating on the name.
12/14/18
DADA
12/14/18
INITIATION
Target $11.5
DADA
Buy
Braemar Hotels & Resorts initiated with a Buy at DA Davidson
DA Davidson analyst James Lykins started Braemar Hotels & Resorts with a Buy rating and $11.50 12-18 month price target. The company has 12 hotels in "highly desirable" markets comprised of luxury and upper upscale hotels and resorts, Lykins tells investors in a research note. He views the stock's current valuation as "appealing."
05/01/19
RILY
05/01/19
DOWNGRADE
RILY
Neutral
Braemar Hotels & Resorts downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Bryan Maher downgraded Bremar Hotels & Resorts to Neutral from Buy with a $14 price target citing valuation and concerns about luxury RevPAR trends pre-Q1 results.
CTG Computer Task Group
$4.47

0.025 (0.56%)

06/15/18
BRRR
06/15/18
UPGRADE
Target $9
BRRR
Outperform
Computer Task Group upgraded to Outperform from Market Perform at Barrington
Barrington analyst Vincent Colicchio upgraded Computer Task Group to Outperform saying the valuation looks favorable following the recent pullback in the shares. Since taking over in July 2016, CEO Bud Crumlish took several actions, including increased investment in the core staffing business and changes to compensation incentives to better align management with shareholders, which has the company's improved growth prospects, Colicchio tells investors in a research note. The analyst has a $9 price target for the stock.
06/15/18
06/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. NV5 Global (NVEE) upgraded to Buy from Neutral at Sidoti. 2. Badger Meter (BMI) upgraded to Hold from Sell at Canaccord with analyst Chip Moore saying the company will continue to benefit from favorable demand for water/flow measurement and conservation technologies in the future, but he feels the current risk/reward is balanced. 3.Charles River (CRL) upgraded to Overweight from Sector Weight at KeyBanc with analyst Donald Hooker saying the stock is one of the best risk-reward stories in the biopharma outsourcing space heading into the second half of 2018. 4. Computer Task Group (CTG) upgraded to Outperform from Market Perform at Barrington with analyst Vincent Colicchio saying the valuation looks favorable following the recent pullback in the shares. 5. Spire (SR) upgraded to Outperform from Market Perform at Wells Fargo with analyst Sarah Akers saying the recent weakness in the shares provides an attractive entry point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CSWC Capital Southwest
$22.27

-0.04 (-0.18%)

07/31/18
JMPS
07/31/18
INITIATION
Target $20
JMPS
Outperform
Capital Southwest initiated with an Outperform at JMP Securities
JMP Securities analyst Christopher York started Capital Southwest Corporation with an Outperform rating and $20 price target, stating that the internally-managed BDC has achieved an "impressive investment track record" since embarking on a credit-focused investment strategy. The balance sheet is unlevered and he expects the portfolio to prudently grow to about $600M, York tells investors.
07/31/18
07/31/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Pampa Energia (PAM) initiated with an Overweight at JPMorgan. 2. Net 1 UEPS (UEPS) initiated with a Buy at Maxim. 3. eXp World Holdings (EXPI) initiated with an Overweight at Stephens. 4. Capital Southwest (csWC) initiated with an Outperform at JMP Securities. 5. WMIH (WMIH) initiated with an Outperform at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/25/19
01/25/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. SS&C (SSNC) initiated with a Buy at Buckingham. 2. Capital Southwest (CSWC) initiated with a Neutral at B. Riley FBR. 3. Natural Gas Services (NGS) initiated with a Buy at Maxim. 4. Aptose Biosciences (APTO) initiated with an Outperform at Oppenheimer. 5. AzurRx BioPharma (AZRX) initiated with a Buy at Roth Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
NLS Nautilus
$3.11

-0.07 (-2.20%)

02/26/19
LSCM
02/26/19
NO CHANGE
Target $8
LSCM
Hold
Nautilus price target lowered to $8 from $11 at Lake Street
Lake Street analyst Chris Krueger lowered his price target for Nautilus shares to $8 saying the company announced Q4 results inline with its recent "weak" preannouncement. The company's new digital platform, Max Intelligence, did not provide the anticipated sales lift management expected and will likely take time to gain traction with consumers as new efforts to drive awareness roll out, Krueger tells investors in a post-earnings research note. He cut his estimates sharply to reflect "poor" near-term visibility and keeps a Hold rating on Nautilus.
02/26/19
IMPC
02/26/19
NO CHANGE
Target $6
IMPC
In-Line
Nautilus price target lowered to $6 at Imperial Capital on uncertain outlook
Imperial Capital analyst George Kelly lowered his estimates for Nautilus for 2019 and cut his price target on the stock to $6 from $7 after the company formally released Q4 results following its pre-release in January and also decided not to provide FY19 guidance, as is customary, citing limited visibility. Kelly, who now estimates direct to decline approximately 23% year-over-year and retail to grow 2%, keeps an In-Line rating on Nautilus shares, adding that he believes the company would benefit from added scale.
05/07/19
LSCM
05/07/19
NO CHANGE
Target $5
LSCM
Hold
Nautilus price target lowered to $5 from $8 at Lake Street
Lake Street analyst Chris Krueger lowered his price target for Nautilus to $5 from $8 saying the company's Q1 results showed large declines for both the company's Direct and Retail segments. Nautilus' new digital platform, Max Intelligence, has not performed well and will likely take time to gain traction with consumers as new efforts to drive awareness roll out, Krueger tells investors in a post-earnings research note. He sees "poor" near-term visibility and keeps a Hold rating on the shares.
05/07/19
DADA
05/07/19
NO CHANGE
Target $5
DADA
Neutral
Nautilus price target lowered to $5 from $8 at DA Davidson
DA Davidson analyst Michael Kawamoto lowered his price target on Nautilus to $5 and kept his Neutral rating after its Q1 earnings miss, saying the company continued to experience pressure from the weaker demand in its Direct product offering amid the "rapidly changing" exercise industry landscape. The analyst notes however that Nautilus management is untertaking several internal initiatives to improve trends, adding that he awaits signs of progress from these efforts before reconsidering his rating.
INSW International Seaways
$19.61

-0.08 (-0.41%)

12/06/18
JEFF
12/06/18
NO CHANGE
Target $30
JEFF
Buy
International Seaways 'very attractive' play on tanker recovery, says Jefferies
After accompanying the management team in client meetings, Jefferies analyst Randy Giveans believes that International Seaways is a "very attractive" way to invest in the sustained tanker recovery "that has just begun." The recent improvement in the crude tanker market is only the beginning of what should be a multi-year recovery, Giveans tells investors in a research note. The analyst keeps a Buy rating on International Seaways with a $30 price target.
10/01/18
JEFF
10/01/18
INITIATION
Target $30
JEFF
Buy
International Seaways initiated with a Buy at Jefferies
Jefferies analyst Randy Giveans started International Seaways with a Buy rating and $30 price target. Tanker demand growth is set to outpace tanker supply growth through at least 2020, Giveans tells investors in a research note. As a result. he believes the crude tanker market is now past the bottom and shipping rates should improve significantly in the coming quarters and years. The analyst calls International Seaways his top crude tanker pick.
11/09/18
RILY
11/09/18
INITIATION
Target $21.5
RILY
Neutral
International Seaways initiated with a Neutral at B. Riley FBR
B. Riley FBR analyst Liam Burke started International Seaways with a Neutral rating and $21.50 price target.
04/24/19
STFL
04/24/19
NO CHANGE
STFL
U.S. sanctions on Iran could benefit crude tankers, says Stifel
After the U.S. recently said it will re-institute sanctions on Iran on May 1 to now include the eight countries that previously had waivers, Stifel analyst Benjamin Nolan said he believes crude tankers could see a benefit. Nolan noted that much of Iran's oil is moved by their own vessels and the net effect could be increased demand for approximately 30 VLCCs from the trio of Saudi Arabia, Russia, and the UAE, who have said they are willing to fill the void left by absent Iranian barrels. Stocks in the crude tanker group include International Seaways (INSW), TEN, Ltd. (TNP), Scorpio Tankers (STNG), Euronav NV (EURN), DHT Holdings (DHT) and Ardmore Shipping (ASC).
FNV Franco-Nevada
$74.16

-1.78 (-2.34%)

05/22/19
RBCM
05/22/19
DOWNGRADE
RBCM
Sector Perform
Franco-Nevada downgraded to Sector Perform from Outperform at RBC Capital
10/10/18
LEHM
10/10/18
INITIATION
Target $70
LEHM
Overweight
Franco-Nevada initiated with an Overweight at Barclays
Barclays analyst Matthew Murphy started Franco-Nevada with an Overweight rating and $70 price target. The analyst rolled out coverage on the North American mining sector with a positive outlook. The current dollar-positive macro dynamic has taken its toll on mining equities, offering investors an attractive entry point to the sector, Murphy tells investors in a research note.
04/09/19
LEHM
04/09/19
DOWNGRADE
LEHM
Equal Weight
Franco-Nevada downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Matthew Murphy downgraded Franco-Nevada to Equal Weight from Overweight.
04/09/19
LEHM
04/09/19
NO CHANGE
LEHM
Barclays still positive on Metals and Mining, downgrades three on valuation
Barclays analyst Matthew Murphy remains positive on shares in the North America Metals and Mining space. The potential for higher recession probabilities could still drive demand for "safe assets," Murphy tells investors in a research note. Further, copper should benefit from a sequential acceleration in China during Q2, says the analyst. He sees several names with "significant upside" and "catalyst potential" including Teck Resources (TECK), Barrick Gold (GOLD), and Newmont Mining (NEM) and Goldcorp (GG). To reflect valuation, Murphy upgraded OceanaGold (OCANF) to Overweight from Equal Weight and downgraded to Equal Weight from Overweight shares of Agnico Eagle (AEM), Franco-Nevada (FNV) and Wheaton Precious Metals (WPM).
DLA Delta Apparel
$22.13

0.6 (2.79%)

02/06/19
ROTH
02/06/19
DOWNGRADE
ROTH
Neutral
Delta Apparel downgraded to Neutral from Buy at Roth Capital
02/06/19
02/06/19
DOWNGRADE
Target $26

Neutral
Delta Apparel downgraded to Neutral at Roth Capital on near-term pressures
As previously reported, Roth Capital analyst Dave King downgraded Delta Apparel to Neutral from Buy, with a $26 price target, given near-term pressures and following the recent run-up in shares. The analyst notes that the company's revenue and EPS exceeded preliminary results, while management said margin pressures from higher raw material costs and Private Label program startup costs should continue into Q2.
LOV Spark Networks
$13.34

0.14 (1.06%)

12/19/18
ADAM
12/19/18
INITIATION
Target $14
ADAM
Buy
Spark Networks initiated with a Buy at Canaccord
Canaccord analyst Austin Moldow initiated Spark Networks with a Buy rating, noting that its recent merger has created the fifth largest dating portfolio measured by subscription revenue. The analyst believes the combined entity's forward growth will be driven by its investment in three U.S. brands. Moldow has a $14 price target on Spark Networks shares.
04/02/19
ADAM
04/02/19
NO CHANGE
Target $19
ADAM
Buy
Spark Networks price target raised to $19 after Zoosk deal at Canaccord
Canaccord analyst Austin Moldow raised his price target on shares of Spark Networks to $19 from $14 following the company's announcement of a deal to combine with Zoosk and after recent "upbeat" investor meetings with Spark's CEO and CFO. The scale gained from the combination with Zoosk has the potential to measurably improve marketing efficiency, said Moldow, who keeps a Buy rating on Spark shares.
MOTS Motus GI Holdings
$3.34

-0.39 (-10.46%)

10/10/18
10/10/18
NO CHANGE
Target $8

Overweight
Piper sees 'favorable' Motus GI data aiding market development efforts
Earlier this morning, Motus GI Holdings presented positive clinical results at the annual American College of Gastroenterology conference, Piper Jaffray analyst Matt O'Brien tells investors in a research note. During the colonoscopy, a baseline visualization score of the colon was taken and compared to the visibility following the use of Matt O'Brien's Pure-Vu. All three study arms demonstrated statistically significant improvement, the analyst adds. He believes these "favorable" results demonstrate the effectiveness of Pure-Vu especially for acute inpatient treatment as well as for patients unable to tolerate conventional bowel prep. Although the study had a relatively small number of patients, it will aid the company's market development efforts in preparation for the 2019 full-commercial Pure-Vu launch, contends O'Brien. He keeps an Overweight rating on Motus GI Holdings with an $8 price target.
03/27/19
PIPR
03/27/19
NO CHANGE
Target $8
PIPR
Overweight
Piper sees 'many catalysts' to move Motus GI shares higher
Piper Jaffray analyst Matt O'Brien reiterates an Overweight rating on Motus GI Holdings with an $8 price target following the company's Q4 results and updates ahead of the expected commercialization of Pure-Vu, still set to begin mid-May. The company reported positive interim findings from its Reduce study as well as announced its expectation to file for a Special 510k for the next-gen Pure-Vu product in the coming months, O'Brien tells investors in a research note. There are "many catalysts" ahead to allow shares of Motus GI to move higher, including the May launch, Gen-2 510k clearance, Reduce readout, and initiation of additional studies, adds the analyst. He recommend micro-cap investors take a look at Motus GI Holdings.
05/10/19
PIPR
05/10/19
NO CHANGE
Target $6
PIPR
Overweight
Motus GI Holdings price target lowered to $6 from $8 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien lowered his price target on Motus GI Holdings to $6 after its Q1 results and an update on its expected commercial launch of the Pure-Vu system in domestic markets. With the full commercial launch of the system in the U.S. expected in the 2nd half of this year, the analyst says FY21 will be the year with "more meaningful penetration rates" in the colonoscopy market. O'Brien also keeps his Overweight rating and sees the current $3.70 per share price as an "attractive entry point" on the stock for the coming months.
02/19/19
PIPR
02/19/19
NO CHANGE
Target $8
PIPR
Overweight
Piper says Motus GI's growing database of data should help upcoming sales effort
After Motus GI announced "yet another study showcasing positive findings for Pure-Vu," Piper Jaffray analyst Matt O'Brien said he views the latest publication in the Journal of Clinical Gastroenterology adding to the growing database of clinical data that should help bolster sales efforts once the company begins commercial launch in May. O'Brien, who expects Motus GI shares to "grind higher from here," keeps an Overweight rating and $8 price target on the stock.
PDFS PDF Solutions
$12.26

-0.14 (-1.13%)

08/29/18
DADA
08/29/18
NO CHANGE
Target $13
DADA
Buy
PDF Solutions price target lowered to $13 from $18 at DA Davidson
DA Davidson analyst Thomas Diffely lowered his price target on PDF Solutions to $13 after yesterday's decision by Global Foundries, to put its 7nm program on hold and to drop its plans to pursue the next generation advanced nodes. The analyst states that while PDF Solutions' exposure to Global Foundries is declining from 40% to 30%, it is still its largest customer, and the announcement has a bearing on its already drifting core yield enhancement business. Diffely keeps his Buy rating on the shares however given the potential upside in the stock price after its 13% slide yesterday.
ELY Callaway Golf
$15.33

0.48 (3.23%)

02/13/19
BREN
02/13/19
INITIATION
Target $24
BREN
Buy
Callaway Golf initiated with a Buy at Berenberg
Berenberg analyst Alex Maroccia initiated Callaway Golf with a Buy and $24 price target. .
01/09/19
01/09/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CarGurus (CARG) initiated with an Outperform at Oppenheimer. 2. Callaway Golf (ELY) and Acushnet Holdings (GOLF) were initiated with an Equal Weight at Stephens. 3. MVB Financial (MVBF) initiated with a Market Perform at Keefe Bruyette. 4. U.S. Steel (X) initiated with a Market Perform at Cowen. 5. Freeport McMoRan (FCX) initiated with a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/13/19
JEFF
02/13/19
NO CHANGE
JEFF
Jefferies says buy Acushnet, Callaway after 600 person golf survey
After surveying over 600 respondents between the ages of 17 and 34 years old in metro statistical areas where there is a Topgolf location, Jefferies analyst Randal Konik recommends buying shares of both Acushnet Holdings (GOLF) and Callaway Golf (ELY). The analyst says the survey supports his thesis that off-course concepts, such as Topgolf, are driving new, and younger, entrants to the sport. The golf industry has undergone a significant transformation over the past decade, and stands to benefit from several key demographic and secular tailwinds, Konik tells investors in a research note. Only around half of Baby Boomers have retired and off-course concepts are growing rapidly and driving new entrants to the sport, Konik says. He views Acushnet as the best-positioned to benefit from an Improving industry backdrop. Further, Callaway's "innovation engine" should help it defend its market share while acquisitions support future growth, the analyst adds.
02/07/19
IMPC
02/07/19
NO CHANGE
Target $22
IMPC
Outperform
Callaway Golf price target lowered to $22 from $25 at Imperial Capital
Imperial Capital analyst George Kelly lowered his price target for Callaway Golf to $22 following the company's "strong" Q4 and initial 2019 guidance. The analyst believes the guidance looks conservative and keeps an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

SEDG

SolarEdge

18:33
06/17/19
06/17
18:33
06/17/19
18:33
Upgrade
SolarEdge rating change  »

SolarEdge upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RUN

Sunrun

$17.09

0.64 (3.89%)

18:33
06/17/19
06/17
18:33
06/17/19
18:33
Upgrade
Sunrun rating change  »

Sunrun upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPWR

SunPower

$8.27

0.03 (0.36%)

18:33
06/17/19
06/17
18:33
06/17/19
18:33
Upgrade
SunPower rating change  »

SunPower upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLSFY

Bluescope Steel

$0.00

(0.00%)

18:32
06/17/19
06/17
18:32
06/17/19
18:32
Hot Stocks
Bluescope Steel cuts FY19 EBIT growth view to up 6% from up 10% »

BlueScope announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

International Flavors

$147.54

-1.25 (-0.84%)

18:24
06/17/19
06/17
18:24
06/17/19
18:24
Hot Stocks
International Flavors CEO: We have planned for Brexit and China is benign for us »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$57.63

-0.65 (-1.12%)

18:24
06/17/19
06/17
18:24
06/17/19
18:24
Periodicals
Senator aims to bar Huawei from seeking damages in patent courts, Reuters says »

U.S. Senator Marco Rubio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 20

    Jun

  • 26

    Jun

  • 27

    Jun

  • 09

    Jul

  • 01

    Aug

BHVN

Biohaven Pharmaceutical

$57.33

-5.63 (-8.94%)

18:12
06/17/19
06/17
18:12
06/17/19
18:12
Hot Stocks
Breaking Hot Stocks news story on Biohaven Pharmaceutical »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISH

Dish

$39.00

1.46 (3.89%)

18:04
06/17/19
06/17
18:04
06/17/19
18:04
Hot Stocks
Dish launches OnTech Smart Services »

Dish announced the launch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$32.30

-0.06 (-0.19%)

18:03
06/17/19
06/17
18:03
06/17/19
18:03
Hot Stocks
AT&T wins 24 GHz spectrum following FCC Auction 102 »

AT&T is the winning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

BHVN

Biohaven Pharmaceutical

$57.33

-5.63 (-8.94%)

18:02
06/17/19
06/17
18:02
06/17/19
18:02
Syndicate
Biohaven Pharmaceutical offers to sell $300M in common stock »

Goldman Sachs & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSM

Versum Materials

$51.42

0.01 (0.02%)

, MKGAY

Merck KGaA

$0.00

(0.00%)

18:01
06/17/19
06/17
18:01
06/17/19
18:01
Hot Stocks
Versum Materials shareholders approve merger with Merck KGaA »

Versum Materials (VSM)…

VSM

Versum Materials

$51.42

0.01 (0.02%)

MKGAY

Merck KGaA

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

VLO

Valero

$76.93

0.19 (0.25%)

18:00
06/17/19
06/17
18:00
06/17/19
18:00
Periodicals
Valero restarting Port Arthur, Texas refinery hydrocracker, Reuters says »

Valero is restarting the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

VLO

Valero

$76.93

0.19 (0.25%)

17:59
06/17/19
06/17
17:59
06/17/19
17:59
Periodicals
Valero restarting Meraux, Louisiana refinery hydrocracker, Reuters says »

Valero is restarting the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

MGI

MoneyGram

$1.44

-0.06 (-4.00%)

17:44
06/17/19
06/17
17:44
06/17/19
17:44
Hot Stocks
MoneyGram spikes almost 140% after blockchain company Ripple investment »

Money transfer company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

JKS

JinkoSolar

$22.59

-2.08 (-8.43%)

17:37
06/17/19
06/17
17:37
06/17/19
17:37
Downgrade
JinkoSolar rating change  »

JinkoSolar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

FCEL

FuelCell

$0.33

-0.0231 (-6.56%)

17:26
06/17/19
06/17
17:26
06/17/19
17:26
Earnings
FuelCell reports Q2 ($2.06), consensus ($2.24) »

Reports Q2 revenue $9.2M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMTI

Rockwell Medical

$4.39

0.2 (4.77%)

17:25
06/17/19
06/17
17:25
06/17/19
17:25
Hot Stocks
Breaking Hot Stocks news story on Rockwell Medical »

Rockwell Medical down 21%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

VRS

Verso

$17.91

-0.24 (-1.32%)

17:21
06/17/19
06/17
17:21
06/17/19
17:21
Hot Stocks
Verso adopts limited duration stockholder rights plan »

Verso announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHVKF

China Vanke Co

$0.00

(0.00%)

17:19
06/17/19
06/17
17:19
06/17/19
17:19
Downgrade
China Vanke Co rating change  »

China Vanke Co downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCKT

Rocket Pharmaceuticals

$16.88

0.68 (4.20%)

17:17
06/17/19
06/17
17:17
06/17/19
17:17
Syndicate
Breaking Syndicate news story on Rocket Pharmaceuticals »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

BA

Boeing

$354.90

7.71 (2.22%)

, EADSY

Airbus

$0.00

(0.00%)

17:17
06/17/19
06/17
17:17
06/17/19
17:17
Periodicals
Boeing gets zero new plane orders at Paris Air Show so far, CNBC says »

According to CNBC's…

BA

Boeing

$354.90

7.71 (2.22%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 09

    Jul

BHVN

Biohaven Pharmaceutical

$57.33

-5.63 (-8.94%)

17:17
06/17/19
06/17
17:17
06/17/19
17:17
Syndicate
Breaking Syndicate news story on Biohaven Pharmaceutical »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MELR

Melrose Bancorp

$18.40

-0.1 (-0.54%)

17:14
06/17/19
06/17
17:14
06/17/19
17:14
Hot Stocks
Breaking Hot Stocks news story on Melrose Bancorp »

Melrose Bancorp trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$55.40

0.66 (1.21%)

17:13
06/17/19
06/17
17:13
06/17/19
17:13
Hot Stocks
Cisco awarded maximum $724.1M Defense Information Systems Agency contract »

Cisco has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 16

    Jul

  • 14

    Aug

NI

NiSource

$29.16

0.41 (1.43%)

17:10
06/17/19
06/17
17:10
06/17/19
17:10
Periodicals
NiSource plans sale of unit tied to gas explosions, Bloomberg says »

According to a story from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.